Multimodal Fetal and Placental Imaging and Biomarkers of Clinical Outcomes in Opioid Use Disorder

Launched by INDIANA UNIVERSITY · May 14, 2024

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• • Pregnant women with opioid use disorder
• Inclusion Criteria:
• • Age \>18 years
• • Currently taking buprenorphine or methadone for OUD and are enrolled in a prenatal opioid maintenance program
• • Singleton Pregnancy
• • Planned delivery at Indiana University or University of Pittsburgh study sites
• Exclusion Criteria:
• • Serious maternal medical illness as deemed by study physician investigators that would make it challenging to comply with study procedures
• • Known or suspected major fetal/ neonatal congenital abnormalities
• • HIV or AIDS
• Infants with prenatal opioid exposure:
• Inclusion:
• • 1. Prenatal buprenorphine or methadone exposure
• • 2. Born to mother enrolled in Opioid Use Disorder arm of study
• Exclusion:
• • Major congenital anomalies or genetic syndromes affecting neurodevelopment
• Control Pregnant Women:
• Inclusion:
• • 1. Women \>18 Years of age
• • 2. Healthy singleton pregnancy
• • 3. Planned delivery at Indiana University or University of Pittsburgh study sites
• Exclusion:
• • 1. Serious maternal medical illness as deemed by study physician investigators that would make it challenging to comply with study procedures
• • 2. HIV or AIDS
• • 3. Known or suspected major fetal congenital abnormalities
• • 4. Any history of opioid misuse before or during pregnancy-per self-report and clinical notes.
• Control infants:
• Inclusion:
• • Born to control pregnant mother enrolled in study
• Exclusion:
• • Any major congenital anomalies, genetic abnormalities, neurologic abnormalities, syndromes, or chronic medical conditions affecting neurodevelopment.